Picture of mobile phone running fintech app

Fintech: Open Access research exploring new frontiers in financial technology

Strathprints makes available Open Access scholarly outputs by the Department of Accounting & Finance at Strathclyde. Particular research specialisms include financial risk management and investment strategies.

The Department also hosts the Centre for Financial Regulation and Innovation (CeFRI), demonstrating research expertise in fintech and capital markets. It also aims to provide a strategic link between academia, policy-makers, regulators and other financial industry participants.

Explore all Strathclyde Open Access research...

Vaccination against Toxoplasmosis : current status and future prospects

Roberts, Craig and McLeod, Rima and Henriquez, Fiona and Alexander, James (2013) Vaccination against Toxoplasmosis : current status and future prospects. In: Toxoplasma Gondii. PERGAMON-ELSEVIER SCIENCE LTD, London, 995–1045. ISBN 9780123964816

Full text not available in this repository. Request a copy from the Strathclyde author


A vaccine capable of protecting against Toxoplasma gondii would have both beneficial medical and veterinary impacts. Successful vaccination of humans would not only reduce mortality and morbidity, but also reduce the financial burden of lifelong care required by those worst affected. A veterinary vaccine would have the dual advantages of increasing livestock productivity while reducing the public health risk associated with eating contaminated meat. Herein we review progress towards these goals using both large animal studies and the murine models of disease. Early approaches were largely empirical and used attenuated organisms, parasite extracts, or defined sub-units based upon the limited genomic data previously available. The recent elucidation of the T. gondii genome, understanding of T. gondii population structures, predicative algorithms for MHC binding peptides, facile manipulation of T. gondii taken together with a wealth of immunological knowledge should significantly promote new vaccine development.